News from takeda pharmaceutical company limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

05 Sep, 2019, 22:26 BST Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the company is issuing a US recall for all doses of...


04 Feb, 2019, 12:00 GMT Takeda to Highlight Advancements in Rare Lysosomal Storage Disorders at Global Scientific Meeting

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will feature 12 presentations, including 11 posters and...


03 Jun, 2018, 13:30 BST Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the...


16 Feb, 2018, 16:00 GMT Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn’s Disease Patients in Comparative Effectiveness Real-World Data Analysis

New clinical study also provides data for Entyvio® in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients...


05 Jan, 2018, 07:00 GMT Takeda Announces Intention to Acquire TiGenix

Expands Takeda's Late Stage Pipeline and Leadership in Gastroenterology Acquisition Highlights Deal reinforces Takeda's commitment to patients living ...


01 Nov, 2017, 08:30 GMT Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio® (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease

New meta-analysis provides a comprehensive view of real-world data and furthers understanding of Entyvio as an important treatment option for...


16 Oct, 2017, 13:06 BST New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients

Takeda Pharmaceutical Company Limited (TSE: 4502), ("Takeda") today announced the presentation of data suggesting early symptomatic improvement in...


02 Aug, 2017, 09:30 BST Takeda and Marvel Custom Solutions Debut the Full IBD Unmasked Graphic Novel Featuring a Team of Inflammatory Bowel Disease (IBD) Super Heroes

Takeda Pharmaceutical Company Limited [TSE: 4502], with the support of Marvel Custom Solutions, today announced the debut of the final two chapters...


19 May, 2017, 07:00 BST Takeda and Marvel Custom Solutions Launch the Latest Adventure of the IBD Unmasked Super Hero Squad in Celebration of World IBD Day 2017

In celebration of World IBD Day, which takes place every year on 19 May, Takeda Pharmaceutical Company Limited [TSE: 4502] with the support of Marvel ...


08 May, 2017, 15:33 BST New Real-World Analyses Support Effectiveness and Safety of Entyvio® (vedolizumab) for Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the presentation of eight real-world analyses supporting the...


30 Mar, 2017, 08:00 BST Takeda Announces Appointment of New President of Europe and Canada Business Unit

Takeda Pharmaceutical Company Limited ("Takeda") announced today that Giles Platford will assume the role of President of the Europe and Canada...


09 Dec, 2016, 14:46 GMT GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab as Induction and Maintenance Therapy in Tumor Necrosis Factor-Naïve Patients with Moderately to Severely Active Crohn's Disease

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that an analysis based on pre-specified and post-hoc exploratory outcomes of...


17 Oct, 2016, 07:00 BST Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") is presenting data on the real-world effectiveness and safety of vedolizumab in...


28 Sep, 2016, 20:27 BST Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that two interim reports from the ongoing, open-label GEMINI long-term safety ...


16 Sep, 2016, 16:43 BST Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that an exploratory analysis of the GEMINI 1 data, evaluating Entyvio...


02 Aug, 2016, 08:07 BST Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the 24-week...


13 Jul, 2016, 07:00 BST IBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community

Takeda unveils new IBD Super Hero and graphic illustrations, developed in collaboration with Marvel Custom Solutions, to highlight the strength of...


05 Jul, 2016, 07:00 BST Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the companies...


11 Jun, 2016, 18:38 BST EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced the publication of a post-hoc analysis from the global EXAMINE (EXamination...


08 Jun, 2016, 13:51 BST Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced...


06 Jun, 2016, 15:39 BST Takeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions

Takeda Pharmaceuticals Company Limited [TSE: 4502], ("Takeda") will present eight abstracts at the American Diabetes Association's 76th Scientific...


23 May, 2016, 17:48 BST Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the oral presentations of two data analyses: one evaluating the optimal ...


12 May, 2016, 14:00 BST Long-Term Integrated Safety Analysis Published in Gut Reports a Favorable Benefit-Risk Profile for Vedolizumab in an Extended Treatment Period

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that an integrated summary of long-term safety data results from six clinical ...


19 Mar, 2016, 08:19 GMT New Data Presented at European Crohn's and Colitis Organisation (ECCO) Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced that the interim findings from the GEMINI Long-Term Safety (LTS) study...


30 Jul, 2015, 15:37 BST Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA

Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the study to fulfill the post-marketing commitment and submissions ...